Interleukin-18 (IL-18) Inhibitor - Pipeline Insight, 2024

Interleukin-18 (IL-18) Inhibitor - Pipeline Insight, 2024

DelveInsight’s, “Interleukin-18 (IL-18) Inhibitor - Pipeline Insight, 2024” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Interleukin-18 (IL-18) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Interleukin-18 (IL-18) Inhibitor: Understanding

Interleukin-18 (IL-18) Inhibitor: Overview

Interleukin-18 (IL-18) is a potent pro-inflammatory cytokine involved in host defense against infections and regulates the innate and acquired immune response. IL-18 is produced by both hematopoietic and non-hematopoietic cells, including monocytes, macrophages, keratinocytes and mesenchymal cell. IL-18 could potentially induce inflammatory and cytotoxic immune cell activities leading to autoimmunity. Its elevated levels have been reported in the blood of patients with some immune-related diseases, including rheumatoid arthritis, systemic lupus erythematosus, type I diabetes mellitus, atopic dermatitis, psoriasis, and inflammatory bowel disease. The broad biological role of the IL-18 cytokine on immune cells have revealed its potential role in inflammatory and autoimmune diseases. IL-18 have been shown to be a diagnostic marker and predictor of inflammatory conditions like myocardial ischemia, acute respiratory distress syndrome , chronic obstructive pulmonary disease, post infectious bronchiolitis obliterans and sepsis-induced multi organ injury. IL-18 has also received increase attention in the pathophysiology of neuro-vascular diseases such as in intracerebral hemorrhage, Japanese encephalitis, ocular Behcet disease, abdominal aortic aneurysm, amyotrophic lateral sclerosis, and glioma and most interestingly in cognitive impairment and agitation in severe mental disease.

Due to the biological properties of IL-18 and its pathological role in different diseases, it is not surprising that drug discovery and therapies are focused on IL-18 and the control of its more pathological outcomes. Using monoclonal antibodies, IL-18 is prevented by inhibiting its production in cells and its secretion from cells.

“Interleukin-18 (IL-18) Inhibitor - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Interleukin-18 (IL-18) Inhibitor pipeline landscape is provided which includes the disease overview and Interleukin-18 (IL-18) Inhibitor treatment guidelines. The assessment part of the report embraces, in depth Interleukin-18 (IL-18) Inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Interleukin-18 (IL-18) Inhibitor collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Interleukin-18 (IL-18) Inhibitor R&D. The therapies under development are focused on novel approaches to treat/improve Interleukin-18 (IL-18) Inhibitor.

Interleukin-18 (IL-18) Inhibitor Emerging Drugs Chapters

This segment of the Interleukin-18 (IL-18) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Interleukin-18 (IL-18) Inhibitor Emerging Drugs

Tadekinig alfa: AB2 Bio Ltd.

Tadekinig alfa is a recombinant Interleukin-18 Binding Protein (r-hIL-18BP) with a high affinity for IL-18, a major inflammatory cytokine. In healthy people, there is a large excess of naturally occurring IL-18BP keeping levels of free IL-18 low. However, in patients with certain inflammatory diseases, the IL-18/IL-18BP balance is disrupted, resulting in high levels of free and active IL-18, which in turn leads to pathological inflammation. Administration of AB2 Bio’s exogenous recombinant human IL-18BP restores the IL-18/IL-18BP balance, removing free IL-18 and thereby reducing inflammation. Currently, the drug is in Phase III stage of its clinical trial for the treatment of XIAP Deficiency.

GSK-1070806: GlaxoSmithKline

GSK-1070806 is under development for the treatment of Crohn’s disease and moderate to severe atopic dermatitis (AtD). The drug candidate is administered intravenously as a solution and subcutaneous route. GSK-1070806 is a humanized IgG1/kappa antibody which is directed against the soluble cytokine interleukin-18 (IL-18). Currently, the drug is in Phase II stage of its clinical trial for the treatment of Atopic Dermatitis.

Further product details are provided in the report……..

Interleukin-18 (IL-18) Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different Interleukin-18 (IL-18) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Interleukin-18 (IL-18) Inhibitor

There are approx. 4+ key companies which are developing the therapies for Interleukin-18 (IL-18) Inhibitor. The companies which have their Interleukin-18 (IL-18) Inhibitor drug candidates in the most advanced stage, i.e. Phase III include, AB2 Bio Ltd.

Phases

DelveInsight’s report covers around 4+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Interleukin-18 (IL-18) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intra-articular

Intraocular

Intrathecal

Intravenous

Oral

Parenteral

Subcutaneous

Topical

Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

Oligonucleotide

Peptide

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Interleukin-18 (IL-18) Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Interleukin-18 (IL-18) Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interleukin-18 (IL-18) Inhibitor drugs.

Interleukin-18 (IL-18) Inhibitor Report Insights

Interleukin-18 (IL-18) Inhibitor Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Interleukin-18 (IL-18) Inhibitor Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Interleukin-18 (IL-18) Inhibitor drugs?

How many Interleukin-18 (IL-18) Inhibitor drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Interleukin-18 (IL-18) Inhibitor?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Interleukin-18 (IL-18) Inhibitor therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Interleukin-18 (IL-18) Inhibitor and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

AB2 Bio Ltd.

Simcha Therapeutics

GlaxoSmithKline

Novartis

Olatec Therapeutics

Compugen

Lassen Therapeutics

Xencor

Bright Peak Therapeutics

Werewolf Therapeutics

Key Products

Tadekinig alfa

ST-067

GSK 1070806

MAS 825

OLT1177

COM 503

LASN 500

XmAb 143

BPT 567

WTX 518